Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Arturo Galvani, Maria Menichincheri et al.|Molecular Cancer Therapeutics|2016Cited by 317
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Antonella Isacchi, Fabio Gasparri et al.|Molecular Oncology|2014Cited by 156
Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and BrachyuryPaola Magnaghi, Antonella Isacchi, Barbara Salom et al.|Molecular Cancer Therapeutics|2017Cited by 93
Abstract A243: Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer modelsElena Ardini, Arturo Galvani, Maria Menichincheri et al.|Molecular Cancer Therapeutics|2009Cited by 31
Establishment and genomic characterization of the new chordoma cell line Chor-IN-1Roberta Bosotti, Antonella Isacchi, Paola Magnaghi et al.|Scientific Reports|2017Cited by 17